Prostaglandin D2 receptor antagonism: a novel therapeutic option for eosinophilic asthma?

Affiliations

¹ Department of Respiratory Medicine, Ghent University Hospital, B-9000 Ghent, Belgium; Department of Epidemiology and Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, Netherlands. Electronic address: guy.brusselle@ugent.be.
² Department of Respiratory Medicine, Ghent University Hospital, B-9000 Ghent, Belgium.

Comment

Guy G Brusselle et al. Lancet Respir Med. 2016 Sep.

. 2016 Sep;4(9):676-677.

doi: 10.1016/S2213-2600(16)30201-6. Epub 2016 Aug 5.

¹ Department of Respiratory Medicine, Ghent University Hospital, B-9000 Ghent, Belgium; Department of Epidemiology and Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, Netherlands. Electronic address: guy.brusselle@ugent.be.
² Department of Respiratory Medicine, Ghent University Hospital, B-9000 Ghent, Belgium.

No abstract available

Comment on

Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Gonem S, Berair R, Singapuri A, Hartley R, Laurencin MFM, Bacher G, Holzhauer B, Bourne M, Mistry V, Pavord ID, Mansur AH, Wardlaw AJ, Siddiqui SH, Kay RA, Brightling CE. Gonem S, et al. Lancet Respir Med. 2016 Sep;4(9):699-707. doi: 10.1016/S2213-2600(16)30179-5. Epub 2016 Aug 5. Lancet Respir Med. 2016. PMID: 27503237 Clinical Trial.